论文部分内容阅读
目的：探讨晚期非小细胞肺癌患者放化疗获益后采用黄芪口服液维持治疗的临床疗效和不良反应。方法选择2012年11月~2015年11月我院80例NSCLC患者，随机分为对照组（n=40）和实验组（n=40）。对照组仅接受定期随访观察，实验组采用参一胶囊维持治疗，比较两组患者治疗后的临床疗效、治疗前后免疫功能、生活质量的变化及不良反应的发生情况。结果实验组患者的疾病控制率明显高于对照组。治疗后，两组患者各免疫功能检测指标均低于治疗前，且实验组明显大于对照组。治疗后，实验组KPS评分提高率明显高于对照组。结论晚期NSCLC患者在放化疗后采用黄芪口服液维持治疗，可显著提高免疫功能、改善生活质量。“,”Objective To investigate the clinical efficacy and safety of Huang-qi oral liquid maintenance therapy after the first-line chemotherapy for patients with advanced non-small cell lung cancer ( NSCLC).Methods 80 patients who responded to the first-line chemotherapy of November 2012 to November 2015 in our hospital were selected, randomly divided into experiment group (n=40) and control group (n=40). The control group were assigned to cilinical observation and experiment group were assigned to Huang-qi oral liquid maintenance therapy. The clinical response and adverse reaction was compared between the two groups. The changes of immune function and quality of life before and after treatment in the two groups were compared.Results The rate of disease control of experimental group was obviously higher than that of control group. After treatment, the immune function indicators in patients with two groups are lower than that of before treatment, and the experimental group significantly greater than the control group. After treatment, the KPS score increase rate of experimental group is significantly higher than that of control group.Conclusion Maintenance therapy of Huang-qi oral liquid is an effective treatment option for patients with advanced NSCLC who have not progressed after first-line therapy.